Shanghai Pharmaceuticals Holding (601607.SH) subsidiary Xinyi Jinzhu has become the licensee for the oral solution of Ammonium Sulfate.

Shanghai Pharmaceuticals Holding (601607.SH) announced that its holding subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd. ("Xinyi Jinzhu"), has received the "Drug Supplementary Application Approval Notice" (Notice No.: 2024B02634) issued by the National Medical Products Administration. The market authorization holder for Amisulpride Oral Solution has been changed to Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd. Amisulpride Oral Solution is mainly used for the treatment of schizophrenia.